epidemiologyЭпидемиология и ВакцинопрофилактикаEpidemiology and Vaccinal Prevention2073-30462619-0494«Numicom» LLC10.31631/2073-3046-2023-22-1-22-27epidemiology-1748Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESПрофилактическая эффективность отечественных вакцин против новой коронавирусной инфекции при иммунизации сотрудников медицинских организацийPreventive Efficacy of Domestic Vaccines against a New Coronavirus Infection in the Immunization of Employees of Medical Organizationshttps://orcid.org/0000-0003-4398-5703ФельдблюмИ. В.FeldblumI. V.

Фельдблюм Ирина Викторовна – доктор медицинских наук, профессор, заведующая кафедрой эпидемиологии и гигиены.

614990, Пермь, ул. Петропавловская, 26

Тел.: +7 (912) 885-32-36

Irina V. Feldblum – Dr. Sci. (Med.), professor, head of the department of epidemiology and hygiene, Academician E.A. Vagner Perm State Medical University of the Ministry of Health of the Russian Federation.

26, Petropavlavskaya street, Perm, 614990

Tel.: +7 (912) 885-32-36

irinablum@mail.ruhttps://orcid.org/0000-0002-3826-7734РепинТ. М.RepinT. M.

Репин Тимофей Максимович – аспирант 2-го года обучения кафедры эпидемиологии и гигиены.

614990, Пермь, ул. Петропавловская, 26

Тел.: +7 (982) 483-69-26

Timofey M. Repin – 2nd year postgraduate student of the department of epidemiology and hygiene, Academician E.A. Vagner Perm State Medical University of the Ministry of Health of the Russian Federation.

26, Petropavlavskaya street, Perm, 614990

Tel.: +7 (982) 483-69-26

timashrepin@yandex.ruhttps://orcid.org/0000-0001-8985-6822ДевятковМ. Ю.DevyatkovM. Y.

Девятков Михаил Юрьевич – кандидат медицинских наук, доцент кафедры эпидемиологии и гигиены.

614990, Пермь, ул. Петропавловская, 26

Тел.: +7 (342) 218-16-68

Michail Yr. Devyatkov – Cand. Sci. (Med.), associate professor of the department of epidemiology and hygiene, Academician E.A. Vagner Perm State Medical University of the Ministry of Health of the Russian Federation.

26, Petropavlavskaya street, Perm, 614990

Tel.: +7 (342) 218-16-68

epidem2005@mail.ruhttps://orcid.org/0000-0003-0962-4269СемериковВ. В.SemerikovV. V.

Семериков Вадислав Васильевич – доктор медицинских наук, заведующий эпидемиологическим отделом.

614000, Пермь, ул. Пушкина, д. 96

Тел.: +7 (919) 479-71-08

Vadislav V. Semyarkov – Dr. Sci. (Med.), head of epidemiological department, Perm Regional Clinical Infectious Diseases Hospital.

96, Pushkina street, Perm, 614000

Tel.: +7 (919) 479-71-08

metodkkib1@yandex.ruhttps://orcid.org/0000-0001-9907-6352ГилеваМ. А.GilevaM. A.

Гилева Мария Александровна – кандидат медицинских наук, заместитель главного  врача  по медицинской части.

614036, Пермь, ул. Бр. Игнатовых, 4.

Тел.: +7 (951) 936-04-23

Maria A. Gileva – Cand. Sci. (Med.), deputy chief medical officer, Regional Clinical Dental Polyclinic.

4, Br. Ignatovih street, Perm, 614036

Tel.: +7 (951) 936-04-23

mgileva75@mail.ruhttps://orcid.org/0000-0003-3399-1691КовтунА. А.KovtunA. A.

Ковтун Анна Александровна – кандидат медицинских наук, врач-стоматолог.

614036, Пермь, ул. Бр. Игнатовых, 4

Тел. +7 (912) 488-77-04

Anna A. Kovtyn – Cand. Sci. (Med.), dentist, KKSP.

4, Br. Ignatovih street, Perm, 614036

Tel.: +7 (912) 488-77-04

kovtunperm@mail.ruhttps://orcid.org/0000-0002-5596-4611МарковичН. И.MarkovichN. I.

Маркович Нина Ивановна – доктор медицинских наук, врач-эпидемиолог.

614068, Пермь, ул. Екатерининская, 224

Тел.: +7 (342) 209-27-54

Nina I. Markovich – Dr. Sci. (Med.), epidemiologist, Perm center for immonoprophylaxis.

224, Ekaterininskaya street, Perm, 614068

Tel.: +7 (342) 209-27-54

barhat120140@mail.ruПермский государственный медицинский университет имени академика Е.А. Вагнера Минздрава РоссииРоссияAcademician E.A. Vagner Perm State Medical University of the Ministry of Health of the Russian FederationRussian FederationПермская краевая клиническая инфекционная больницаРоссияState Budgetary Healthcare Institution of Perm Krai «Perm Regional Clinical Infectious Diseases HospitalRussian FederationКраевая клиническая стоматологическая поликлиникаРоссияState Budgetary Healthcare Institution of Perm Krai «Regional Clinical Dental PolyclinicRussian FederationПермский центр иммунопрофилактикиРоссияPerm center of immunoprophylaxisRussian Federation2023050320232212227Copyright © Фельдблюм И.В., Репин Т.М., Девятков М.Ю., Семериков В.В., Гилева М.А., Ковтун А.А., Маркович Н.И., 20232023Фельдблюм И.В., Репин Т.М., Девятков М.Ю., Семериков В.В., Гилева М.А., Ковтун А.А., Маркович Н.И.Feldblum I.V., Repin T.M., Devyatkov M.Y., Semerikov V.V., Gileva M.A., Kovtun A.A., Markovich N.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.epidemvac.ru/jour/article/view/1748

Актуальность. Оценка профилактической эффективности отечественных вакцин при иммунизации сотрудников медицинских организаций в условиях пандемии, вызванной вирусом SARS-CoV-2, сохраняет свою значимость. Цель. Оценить профилактическую эффективность отечественных вакцин при иммунизации сотрудников медицинских организаций. Материалы и методы. Профилактическая эффективность отечественных вакцин изучена в эпидемиологическом, аналитическом, ретроспективном, когортном, параллельном исследовании с участием 1115 медицинских работников из различных амбулаторно-поликлинических организаций г. Перми. Результаты. В условиях аналитического когортного исследования установлена высокая профилактическая эффективность вакцинопрофилактики COVID-19 сотрудников медицинских организаций – заболеваемость непривитых в 3,3 раза превышала заболеваемость привитых. У привитых в 2,8 раза реже регистрировались среднетяжёлые клинические формы COVID-19 и отсутствовали тяжёлые. Наибольший коэффициент профилактической эффективности у вакцин Гам-Ковид-Вак и Спутник Лайт (76,1 и 78,2% соответственно), ниже – у вакцин Ковивак (54,53%) и ЭпиВакКорона (50,1%). Заключение. Все отечественные вакцины характеризуются профилактической эффективностью, предупреждают не только развитие тяжёлых клинических форм инфекции, но и снижают риски инфицирования. Наиболее эффективны вакцины Гам-Ковид-Вак и Спутник Лайт.

Relevance. Evaluation of the preventive effectiveness of domestic vaccines in immunization of employees of medical organizations, in the context of the ongoing pandemic caused by the SARS-CoV-2 virus, remains important. The aim. To evaluate the preventive effectiveness of domestic vaccines in the immunization of employees of medical organizations. Materials and methods. The preventive efficacy of domestic vaccines was studied in an epidemiological, analytical, retrospective (historical), cohort, parallel study involving 1115 healthcare workers from various outpatient and policlinic organizations in the city of Perm. Results. The high preventive efficacy of COVID-19 vaccination of health care workers was established in the conditions of analytical cohort study (the incidence of the unvaccinated was 3.3 times higher than the incidence of vaccinated). Among the vaccinated, a milder course of the disease was observed. The GamCovidVac Spuntic V and Sputnik Light vaccines were characterized by the highest prophylactic efficacy for which was 76.1 and 78.2 respectively, against 54.53 with Covivac immunization and 50.7 with EpiVacCorona. Conclusions. Vaccination is an effective measure against COVID-19 and can be recommended in the context of ongoing pandemic.

COVID-19заболеваемостьсотрудники медицинских организацийиммунизацияотечественные вакциныпрофилактическая эффективностьCOVID-19incidenceemployees of medical organizationsdomestic vaccinesprophylactic efficacyReferencesBchetnia M, Girard C, Duchaine C, Laprise C. The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status. J Infect Public Health. 2020 Nov;13(11):1601–1610. doi: 10.1016/j.jiph.2020.07.011. Epub 2020 Aug 4. PMID: 32778421; PMCID: PMC7402212.Bchetnia M, Girard C, Duchaine C, Laprise C. The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status. J Infect Public Health. 2020 Nov;13(11):1601–1610. doi: 10.1016/j.jiph.2020.07.011. Epub 2020 Aug 4. PMID: 32778421; PMCID: PMC7402212.Hughes M.M., Groenewold M.R., Lessem S.E., et al. Update: Characteristics of HealthCare Personnel with COVID-19 - United States, February 12-July 16, 2020. MMWR Morb Mortal Wkly Rep. 2020. Vol. 69. N. 38. P. 1364–1368.Hughes M.M., Groenewold M.R., Lessem S.E., et al. Update: Characteristics of HealthCare Personnel with COVID-19 - United States, February 12-July 16, 2020. MMWR Morb Mortal Wkly Rep. 2020. Vol. 69. N. 38. P. 1364–1368.Kambhampati AK, O’Halloran AC, Whitaker M, et al. COVID-19–Associated Hospitalizations Among Health Care Personnel – COVID-NET, 13 States, March 1–May 31, 2020. MMWR Morb Mortal Wkly Rep 2020; 69:1576–1583. DOI:http://dx.doi.org/10.15585/mmwr.mm6943e3Kambhampati AK, O’Halloran AC, Whitaker M, et al. COVID-19–Associated Hospitalizations Among Health Care Personnel – COVID-NET, 13 States, March 1–May 31, 2020. MMWR Morb Mortal Wkly Rep 2020; 69:1576–1583. DOI: http://dx.doi.org/10.15585/mmwr.mm6943e3.Treibel T.A., Manisty C., Burton M., et al. COVID-19: PCR screening of asymptomatic health-care workers at London hospital. Lancet. 2020. Vol. 395. N10237. P.1608–1610. DOI: 10.1016/S0140-6736(20)31100-4Treibel T.A., Manisty C., Burton M., et al. COVID-19: PCR screening of asymptomatic health-care workers at London hospital. Lancet. 2020. Vol. 395. N10237. P.1608–1610. DOI: 10.1016/S0140-6736(20)31100-4.Hunter E, Price DA, Murphy E, et al. First experience of COVID-19 screening of health-care workers in England. Lancet. 2020 May 2;395(10234): e77–e78. doi: 10.1016/S0140-6736(20)30970-3. Epub 2020 Apr 22. PMID: 32333843; PMCID: PMC7176380.Hunter E., Price D.A., Murphy E., et al. First experience of COVID-19 screening of health-care workers in England. LСмancet. 2020. Vol. 395. N10234. P.77–78. DOI: 10.1016/S0140-6736(20)30970-3.Nguyen L. H., Drew D. A., Joshi A. D., et al. Risk of COVID-19 among frontline healthcare workers and the general community: a prospective cohort study. // Lancet Public Health. 2020. N 5. P. 475–483. DOI:https://doi.org/10.1016/S2468-2667(20)30164-XNguyen L. H., Drew D. A., Joshi A. D., et al. Risk of COVID-19 among frontline healthcare workers and the general community: a prospective cohort study. // Lancet Public Health. 2020. N 5. P. 475–483. DOI:https://doi.org/10.1016/S2468-2667(20)30164-X.Курылев А. А., Журавков А. А., Колбин А. С. Анализ эффективности вакцинации от COVID-19 на основании данных реальной клинической практики в Санкт-Петербурге. Качественная Клиническая Практика. 2021;(4):80–84. https://doi.org/10.37489/2588-0519-2021-4-80-84Kurylev A.A., Zhuravkov A.A., Kolbin A.S. Analysis of the effectiveness of vaccination against COVID-19 based on real-world data in St. Petersburg. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2021;(4):80-84. (In Russ.) https://doi.org/10.37489/2588-0519-2021-4-80-84.Дмитриев А.В., Федина Н. В., Ткаченко Т. Г. и др. Приверженность вакцинопрофилактике студентов-медиков и врачей-педиатров в период пандемии COVID-19. Медицинский совет. 2021;(11):202–209. https://doi.org/10.21518/2079-701X-2021-11-202-209.Dmitriev A.V., Fedinа N.V., Tkachenko T.G., et al. Preventive vaccination compliance among medical students and pediatricians during the COVID-19 pandemic. Meditsinskiy sovet = Medical Council. 2021;(11):202–209. (In Russ.) https://doi.org/10.21518/2079-701X-2021-11-202-209Palamenghi L, Barello S, Boccia S, Graffigna G. Mistrust in biomedical research and vaccine hesitancy: the forefront challenge in the battle against COVID-19 in Italy. EurJ-Epidemiol. 2020 Aug;35(8):785–788. doi: 10.1007/s10654-020-00675-8.Palamenghi L, Barello S, Boccia S, Graffigna G. Mistrust in biomedical research and vaccine hesitancy: the forefront challenge in the battle against COVID-19 in Italy. EurJ-Epidemiol. 2020 Aug;35(8):785–788. doi: 10.1007/s10654-020-00675-8.Голубкова А. А., Платонова Т. А., Семененко Т. А. и др. Многоуровневый мониторинг приверженности прививкам различных групп населения в условиях пандемии COVID-19: проблемные вопросы. Эпидемиология и Вакцинопрофилактика. 2021;20(6): 28–36. https://doi:10.31631/2073-3046-2021-20-6-28-36.Golubkova A.A., Platonova T.A., Semenenko T.A., Smirnova S.S., Nikitskaya A.D., Chikunova M.V. Multi-Level Monitoring of Vaccination Adherence of Various Population Groups in the Context of the COVID-19 Pandemic: Problematic Issues. Epidemiology and Vaccinal Prevention. 2021;20(6):28–36. (In Russ.) https://doi.org/10.31631/2073-3046-2021-20-6-28-36.Randolph HE, Barreiro LB. Herd Immunity: Understanding COVID-19. Immunity. 2020; 52 (5): 737–741. doi: 10.1016/j.immuni.2020.04.012.Randolph HE, Barreiro LB. Herd Immunity: Understanding COVID-19. Immunity. 2020; 52 (5): 737–741. doi: 10.1016/j.immuni.2020.04.012.Lourenço J, Paton R, Thompson C, Klenerman P, Gupta S. Fundamental principles of epidemic spread highlight the immediate need for large-scale serological surveys to assess the stage of the SARS-CoV-2 epidemic. MedRxiv. 2029; 2004229. doi: 10.1101/2020.03.24.2004229.Lourenço J, Paton R, Thompson C, Klenerman P, Gupta S. Fundamental principles of epidemic spread highlight the immediate need for large-scale serological surveys to assess the stage of the SARS-CoV-2 epidemic. MedRxiv. 2029; 2004229. doi.org/10.1101/2020.03.24.2004229.Vignesh R, Shankar EM, Velu V, Thyagarajan SP. Is Herd Immunity Against SARS-CoV-2 a Silver Lining? Front Immunol. 2020; 11: 586781. doi: 10.3389/fimmu.2020.586781Vignesh R, Shankar EM, Velu V, Thyagarajan SP. Is Herd Immunity Against SARS-CoV-2 a Silver Lining? Front Immunol. 2020; 11: 586781. doi: 10.3389/fimmu.2020.586781Попова А. Ю., Ежлова Е. Б., Мельникова А. А. и др. Популяционный иммунитет к SARS-CoV-2 среди населения Санкт-Петербурга в период эпидемии COVID-19. Проблемы особо опасных инфекций. 2020;(3):124–130. https://doi.org/10.21055/0370-1069-2020-3-124-130.Popova A.Yu., Ezhlova E.B., Melnikova A.A., et al. Herd Immunity to SARS-CoV-2 among the Population in Saint-Petersburg during the COVID-19 Epidemic. Problems of Particularly Dangerous Infections. 2020;(3):124–130. (In Russ.) https://doi.org/10.21055/0370-1069-2020-3-124-130Logunov, D.Y., Dolzhikova, I.V., Shcheblyakov, D.V., et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 2021, 397, 671–681, doi:10.1016/S0140-6736(21)00234-8.Logunov, D.Y.; Dolzhikova, I.V.; Shcheblyakov, D.V., et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 2021, 397, 671–681, doi:10.1016/S0140-6736(21)00234-8.Vokó Z, Kiss Z, Surján G. Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary – The HUN-Estudy.ClinicalMicrobiologyandInfection2021,2021 DOI:https://doi.org/10.1016/j.cmi.2021.11.011Vokó Z, Kiss Z, Surján G. Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary - The HUN-Estudy.ClinicalMicrobiologyandInfection2021,2021 DOI:https://doi. org/10.1016/j.cmi.2021.11.011Намазова-Баранова Л. С., Федосеенко М. В., Шахтахтинская Ф. Ч. и др. Эффективностьибезопасностьиммунизациипептиднойвакцинойдляпрофилактики инфекции, вызванной SARS-CoV-2: проспективное исследование среди медицинских работников. Вопросы современной педиатрии. 2022;21(2):83–94. doi: https://doi.org/10.15690/vsp.v21i2.2386.Namazova-Baranova Leyla S., Fedoseenko Marina V., Shakhtakhtinskaya Firuza Ch., et al. Efficacy and Safety of Peptide Vaccine in Prevention of SARS-CoV-2 Infection: Prospective Study among Healthcare Professionals. Voprosy sovremennoi pediatrii — Current Pediatrics. 2022;21(2):83–94. (In Russ). doi: https://doi.org/10.15690/vsp.v21i2.2386.Рыжиков А.Б., Рыжиков Е.А., Богрянцева М.П. и др. Простое слепое плацебо-контролируемое рандомизированное исследование безопасности, реактогенности и иммуногенности вакцины «ЭпиВакКорона» для профилактики COVID-19 на добровольцах в возрасте 18–60 лет (фаза I–II) // Инфекция и иммунитет. 2021. Т. 11, № 2. С. 283–296.Ryzhikov A.B., Ryzhikov E.A., Bogryantseva M.P., et al. A simple blind placebocontrolled randomized study of the safety, reactogenicity and immunogenicity of the EpiVac Corona vaccine for the prevention of COVID-19 on volunteers aged 18–60 years (phase I–II). Infektsiya i immunitet [Russian Journal of Infection and Immunity]. 2021; 11 (2): 283–96. (in Russian). DOI: https://doi.org/10.15789/2220-7619-ASB-1699 15. Temporary methodological recommendations “Procedure for vaccination of the adult population against COVID-19”; 2021. (in Russian).Сергиенко Д. Ф., Кузьмин Е. А., Эмеева З. Ю. и др. Вакцинация от COVID 19: предрассудки, предубеждения и истина // Астраханский медицинский журнал. 2022. Т. 17, No 2. С. 14–20. doi: 10.48612/agmu/2022.17.2.14.20.Sergienko D. F., Kuz’min E. A., Emeeva Z. Y., Kosareva A. R., Abdulaeva P. M., Pogosyan K. A., Zaplavnyy V. M. Vaccination against COVID 19: prejudice, preconception and truth. Astrakhan Medical Journal. 2022; 17 (2): 14–20. doi: 10.48612/agmu/2022.17.2.14.20 (In Russ.).Barchuk A, BulinaA, Cherkashin M, et al. COVID-19 vaccines effectiveness against symptomatic SARS-CoV-2 Delta variant infection: a population-based case-control study in St. Petersburg, Russia. Now published in BMC Public Health. doi:10.1186/s12889-022-14202-9.Barchuk A, BulinaA, Cherkashin M, et al. COVID-19 vaccines effectiveness against symptomatic SARS-CoV-2 Delta variant infection: a population-based case-control study in St. Petersburg, Russia. Now published in BMC Public Health. doi:10.1186/s12889-022-14202-9Logunov, D.Y., Dolzhikova, I.V., Zubkova, O.V., et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1/2 studies from Russia. Lancet 2020, 396, 887–897.Logunov, D.Y., Dolzhikova, I.V., Zubkova, O.V., et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1/2 studies from Russia. Lancet 2020, 396, 887–897.Dolzhikova, I.V., Gushchin, V.A., Shcheblyakov, D.V., et al. One-shotimmunization with Sputnik Light (the first component of Sputnik V vaccine) is effective againstSARS-CoV-2 Delta variant: efficacy data on the use of the vaccine in civil circulation in Moscow.medRxiv2021,10.1101/2021.10.08.21264715, doi:10.1101/2021.10.08.21264715.Dolzhikova, I.V.; Gushchin, V.A.; Shcheblyakov, D.V., et al. One-shotimmunization with Sputnik Light (the first component of Sputnik V vaccine) is effective againstSARS-CoV-2 Delta variant: efficacy data on the use of the vaccine in civil circulation in Moscow.medRxiv2021,10.1101/2021.10.08.21264715, doi:10.1101/2021.10.08.21264715.González S, Olszevicki S, Salazar M, Calabria A, et al. Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina. EClinicalMedicine. Volume 40.2021.101126. ISSN 2589–5370. https://doi.org/10.1016/j.eclinm.2021.101126.González S, Olszevicki S, Salazar M, Calabria A, et al. Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina. EClinicalMedicine. Volume 40.2021.101126. ISSN 2589–5370. https://doi. org/10.1016/j.eclinm.2021.101126.Kolobukhina L.V., Burgasova O.A., Kruzhkova I.S., et al. Assessment of COVID-19 clinical course in patients vaccinated with Sputnik V, SARS-CoV-2 S protein RBD domain variation and serum virus neutralizing activity. Bulletin of Russian State Medical University 2021; (5):62–70. https://doi.org/10.24075/brsmu.2021.046.Kolobukhina L.V., Burgasova O.A., Kruzhkova I.S., et al. Assessment of COVID-19 clinical course in patients vaccinated with Sputnik V, SARS-CoV-2 S protein RBD domain variation and serum virus neutralizing activity. Bulletin of Russian State Medical University 2021; (5):62–70. https://doi.org/10.24075/brsmu.2021.046Butt A.A., Nafady-Hego H., Chemaitelly H., et al. Outcomes Among Patients with Breakthrough SARS-CoV-2 Infection After Vaccination. Int. J. Infect. Dis. 2021; 110:353–358. https://doi.org/10.1016/j.ijid.2021.08.008Butt A.A., Nafady-Hego H., Chemaitelly H., Abou-Samra A.B., Khal A.A., Coyle P.V., Kanaani Z.A., Kaleeckal A.H., Latif A.N., Masalmani Y.A., Bertollini R., Raddad L. Outcomes Among Patients with Breakthrough SARS-CoV-2 Infection After Vaccination. Int. J. Infect. Dis. 2021; 110:353–358. https://doi.org/10.1016/j.ijid.2021.08.008.

The authors declare that there are no conflicts of interest present.